Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.

Gössi, Ursina; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Vera Ulrike; Novak, Urban; Betticher, Daniel; Egger, Thomas; Zander, Thilo; Pabst, Thomas (2018). Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematological oncology, 36(2), pp. 436-444. Wiley 10.1002/hon.2490

[img] Text
2nd ASCT Gössi Hemat Onc 2018.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (296kB)

Autologous stem cell transplantation (ASCT) as part of the primary therapy in multiple myeloma (MM) is standard practice. In contrast, the role of a second ASCT (ASCT2) and subsequent lenalidomide maintenance for relapsed disease remains unclear. In this study, we analysed 86 consecutive MM patients with a first relapse after prior ASCT receiving either a second ASCT or conventional chemotherapy. After a median follow-up of 37.7 months since first relapse, 54 (62.8%) patients were still alive and 29 (33.7%) without progression. Sixty-one (71.0%) patients received ASCT2 and had better progression-free survival (PFS) (30.2 versus 13.0 mo; P = .0262) and overall survival (OS) rates (129.6 versus 33.5 mo; P = .0003) compared with 25 (29.0%) patients with conventional treatment. Patients relapsing later than 12 months after ASCT1 benefitted from a second ASCT with better PFS2 (P = .0179) and OS2 (P = .0009). Finally, lenalidomide maintenance after ASCT2 was associated with longer PFS (41.0 vs 21.6 mo; P = .0034) and better OS (not yet reached vs 129.6 mo; P = .0434) compared with patients without maintenance. Our data suggest that a second ASCT and lenalidomide maintenance given at first relapse in MM after prior ASCT are associated with better survival rates.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.)

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Jeker, Barbara, Mansouri Taleghani, Behrouz, Bacher, Vera Ulrike, Novak, Urban, Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1099-1069

Publisher:

Wiley

Language:

English

Submitter:

Nicole Corminboeuf

Date Deposited:

16 Apr 2018 14:55

Last Modified:

02 Mar 2023 23:30

Publisher DOI:

10.1002/hon.2490

PubMed ID:

29363149

Uncontrolled Keywords:

autologous chemotherapy high-dose lenalidomide maintenance myeloma relapse salvage stem cell survival transplant

BORIS DOI:

10.7892/boris.111445

URI:

https://boris.unibe.ch/id/eprint/111445

Actions (login required)

Edit item Edit item
Provide Feedback